{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:46:55Z","timestamp":1779151615169,"version":"3.51.4"},"reference-count":30,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T00:00:00Z","timestamp":1523923200000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Daiichi Sankyo Europe GmbH (M\u00fcnchen, Germany)"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Cardiology"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:p>Patients with atrial fibrillation (AF) are at an approximately 0.5% to 3% increased risk of thromboembolism during and immediately after catheter ablation. Treatment guidelines recommend periprocedural oral anticoagulation plus unfractionated heparin during ablation. Rivaroxaban and dabigatran are the only non\u2013vitamin K oral anticoagulants for which there are randomized controlled trials assessing uninterrupted anticoagulation in patients undergoing catheter ablation of AF. Edoxaban, a direct factor Xa inhibitor, is noninferior vs warfarin for the prevention of stroke or systemic embolism with less major bleeding in patients with nonvalvular AF. The ELIMINATE\u2010AF (Evaluation of Edoxaban Compared With VKA in Subjects Undergoing Catheter Ablation of Nonvalvular Atrial Fibrillation) trial is a multinational, multicenter, prospective, randomized, open\u2010label, parallel\u2010group, blinded\u2010endpoint evaluation (PROBE) study to assess the safety and efficacy of once\u2010daily edoxaban 60\u2009mg (30\u2009mg in patients indicated for a dose reduction) vs vitamin K antagonists (VKA) in patients with nonvalvular AF undergoing catheter ablation (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.clinicaltrials.gov\">http:\/\/www.ClinicalTrials.gov<\/jats:ext-link>: NCT02942576). A total of 560 patients are planned for randomization to edoxaban or VKA (2:1 ratio) to obtain 450 patients fully compliant with the protocol. Patients will complete 21 to 28\u2009days of anticoagulation prior to the ablation and a 90\u2010day post\u2010ablation period. The primary efficacy endpoint is the composite of all\u2010cause death, stroke, and major bleeding. The primary safety endpoint is major bleeding. A magnetic resonance imaging substudy will assess the incidence of silent cerebral lesions post\u2010ablation. ELIMINATE\u2010AF will define the efficacy and safety of edoxaban for uninterrupted oral anticoagulation during catheter ablation of AF.<\/jats:p>","DOI":"10.1002\/clc.22918","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T08:58:20Z","timestamp":1523955500000},"page":"440-449","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE\u2010AF study."],"prefix":"10.1002","volume":"41","author":[{"given":"Stefan H.","family":"Hohnloser","sequence":"first","affiliation":[{"name":"Division of Clinical Electrophysiology, Department of Cardiology J.W. Goethe University  Frankfurt Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Camm","sequence":"additional","affiliation":[{"name":"Cardiology Clinical Academic Group, Molecular and Clinical Sciences Research Institute St. George's University of London  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Cappato","sequence":"additional","affiliation":[{"name":"Arrhythmia and Electrophysiology Research Center Humanitas Clinical and Research Center  Rozzano Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans\u2010Christoph","family":"Diener","sequence":"additional","affiliation":[{"name":"Department of Neurology University Hospital Essen and Medical Faculty of the University Duisburg\u2010Essen  Essen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hein","family":"Heidbuchel","sequence":"additional","affiliation":[{"name":"Department of Cardiology Antwerp University Hospital, University of Antwerp  Antwerp Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans\u2010Joachim","family":"Lanz","sequence":"additional","affiliation":[{"name":"Department of Global Medical Affairs Daiichi\u2010Sankyo Europe GmbH  Munich Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Llu\u00eds","family":"Mont","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Clinic University of Barcelona  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos A.","family":"Morillo","sequence":"additional","affiliation":[{"name":"Department of Cardiac Sciences, Division of Cardiology, Libin Cardiovascular Institute University of Calgary  Calgary Alberta Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00fcdiger","family":"Smolnik","sequence":"additional","affiliation":[{"name":"Department of Global Medical Affairs Daiichi\u2010Sankyo Europe GmbH  Munich Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ophelia Q.P.","family":"Yin","sequence":"additional","affiliation":[{"name":"Pharma Development, Modeling, and Simulation, Daiichi\u2010Sankyo  Basking Ridge New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef","family":"Kautzner","sequence":"additional","affiliation":[{"name":"Department of Cardiology Institute for Clinical and Experimental Medicine  Prague Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,4,17]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.108.824789"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.109.859116"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.03.022"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eus027"},{"key":"e_1_2_6_6_1","first-page":"50.e1","article-title":"2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS [article in English, Spanish; published correction appears in Rev Esp Cardiol (Engl Ed). 2017;70:1031]","volume":"70","author":"Kirchhof P","year":"2017","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.641225"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2009.11.031"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.006426"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62343-0"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2017.05.012"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701005"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv177"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0342-7"},{"key":"e_1_2_6_15_1","volume-title":"Parsippany","author":"Savaysa (edoxaban) tablets [full prescribing information]","year":"2015"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310907"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2017.05.098"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu181"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-01-0066"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2010.03975.x"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.009449"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.76.1.142"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.04.010"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2011.06.030"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8167.2012.02420.x"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10840-016-0221-7"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2014.05.038"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2015.03.102"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eut241"},{"key":"e_1_2_6_30_1","first-page":"e448","article-title":"Clinical benefit of minimally interrupted dabigatran versus uninterrupted warfarin for catheter ablation of atrial fibrillation: a prospective randomized multicenter trial","volume":"136","author":"Nogami A","year":"2017","journal-title":"Circulation"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euw368"}],"container-title":["Clinical Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fclc.22918","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clc.22918","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T18:41:12Z","timestamp":1695494472000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clc.22918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1002\/clc.22918"],"URL":"https:\/\/doi.org\/10.1002\/clc.22918","archive":["Portico"],"relation":{},"ISSN":["0160-9289","1932-8737"],"issn-type":[{"value":"0160-9289","type":"print"},{"value":"1932-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"2017-11-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}